Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of 4-aminoquinolines. It features a quinoline core substituted with amino and fluoro groups and incorporates a trifluoromethylated ethanediol moiety. The presence of fluorine atoms and the quinoline scaffold suggest potential for biological activity—such as enzyme inhibition or receptor modulation—commonly explored in medicinal chemistry for anti-infective or anticancer properties. However, there is no evidence that this compound has been approved for any indication or entered clinical trials. Its mechanism of action remains uncharacterized in public databases[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-[3-({[(4-amino-5-fluoro-2-methylquinolin-3-yl)methyl]thio}methyl)phenyl]-2,2,2-trifluoroethane-1,1-diol.